Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 10:14:537-546.
doi: 10.2147/CEOR.S368780. eCollection 2022.

Real-World Evaluation of Clinical Response and Long-Term Healthcare Resource Utilization Patterns Following Treatment with a Digital Therapeutic for Chronic Insomnia

Felicia Forma  1 , Tyler G Knight  2 , Frances P Thorndike  1 , Xiaorui Xiong  1 , Rebecca Baik  2 , Fulton F Velez  1 , Yuri A Maricich  1 , Daniel C Malone  3
Affiliations

Real-World Evaluation of Clinical Response and Long-Term Healthcare Resource Utilization Patterns Following Treatment with a Digital Therapeutic for Chronic Insomnia

Felicia Forma et al. Clinicoecon Outcomes Res. .

Abstract

Background and objectives: This analysis evaluated insomnia severity and long-term impact on healthcare resource utilization (HCRU) and costs after treatment with Somryst® (previously called SHUTi), a digital therapeutic delivering cognitive behavioral therapy for insomnia (CBT-I).

Methods: Change from baseline in insomnia severity index (ISI) score was assessed using last observed ISI score. A pre/post analysis of claims data was conducted, comparing HCRU in patients with self-identified sleep problems who successfully initiated the therapeutic (index date) between June 1, 2016 and December 31, 2018.

Results: A total of 248 patients were analyzed (median age 56.5 years, 57.3% female, mean ISI score 19.13, 52.4% treated with sleep aid medications pre-index). After 9 weeks, mean ISI score declined by 37.2% from baseline (19.1 vs 12.0), 58.8% of patients achieved ISI responder status (ISI score improved by =>7; NNT: 1.7), and 26.6% of patients achieved insomnia remission (ISI score <8; NNT for remission: 3.8). After two-year follow-up, post-index events were reduced (compared to 2 years pre-index) for emergency department visits (-53%; IRR: 0.47; 95% CI 0.27, 0.82; P=0.008), hospiatizations (-21%; IRR: 0.79; 95% CI 0.46, 1.35; P=0.389) and hospital outpatient visits (-13%; IRR: 0.87; 95% CI 0.66, 1.14; P=0.315). Slightly increased rates were observed for ambulatory surgical center visits (2%; IRR: 1.02; 95% CI 0.73, 1.44; P=0.903) and office visits (2%; IRR: 1.02; 95% CI 0.92, 1.14; P=0.672). The number of patients treated with sleep aid medications dropped 18.5% (52.4% pre-index vs 42.7% post-index). Average number of prescriptions decreased from 3.98 pre-index to 3.73 post-index (P= 0.552). Total two-year cost reduction post-index vs pre-index was $510,678, or -$2059 per patient.

Conclusion: In a real-world cohort of patients with chronic insomnia, treatment with a digital therapeutic delivering CBT-I was associated with reductions in insomnia severity, emergency department visits, and net costs.

Keywords: CBT-I; SHUTi; Somryst; chronic insomnia; cognitive behavioral therapy for insomnia; prescription digital therapeutic.

PubMed Disclaimer

Conflict of interest statement

FF, FPT, XX, FFV, and YAM are employees of Pear Therapeutics (US), Inc. FPT also reports equity and employment from BeHealth Solutions, during the conduct of the study; and was a previous faculty member at institution (University of Virginia) that developed precursor (SHUTi) to this work. TGK and RB are employees of Market Access Consulting, Labcorp Drug Development, which participated in this study under contract with Pear Therapeutics (US), Inc. DCM is a consultant of Strategic Therapeutics, LLC, which participated in this study under contract with Pear Therapeutics (US), Inc. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
CONSORT diagram.
See this image and copyright information in PMC

References

    1. Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med. 2007;3(5 Suppl):S7–S10. doi: 10.5664/jcsm.26929 - DOI - PMC - PubMed
    1. LeBlanc M, Merette C, Savard J, Ivers H, Baillargeon L, Morin CM. Incidence and risk factors of insomnia in a population-based sample. Sleep. 2009;32(8):1027–1037. doi: 10.1093/sleep/32.8.1027 - DOI - PMC - PubMed
    1. Leger D, Poursain B. An international survey of insomnia: under-recognition and under-treatment of a polysymptomatic condition. Curr Med Res Opin. 2005;21(11):1785–1792. doi: 10.1185/030079905X65637 - DOI - PubMed
    1. Sivertsen B, Krokstad S, Mykletun A, Overland S. Insomnia symptoms and use of health care services and medications: the HUNT-2 study. Behav Sleep Med. 2009;7(4):210–222. doi: 10.1080/15402000903190199 - DOI - PubMed
    1. Morin CM, Carrier J, Bastien C, Godbout R, Canadian S, Circadian N. Sleep and circadian rhythm in response to the COVID-19 pandemic. Can J Public Health. 2020;111:654–657. doi: 10.17269/s41997-020-00382-7 - DOI - PMC - PubMed